• Most Popular
  • Most Shared

REUTERS SHOWCASE

New Antibiotics

New Antibiotics

U.S. government taps GlaxoSmithKline for new antibiotics  Full Article 

Medical Marijuana

Medical Marijuana

Los Angeles voters OK move to curtail medical marijuana outlets  Full Article 

Birdflu Cost

Birdflu Cost

China's bird flu outbreak cost $6.5 billion  Full Article 

Group Workouts

Group Workouts

Putting group fitness classes in the proper light  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

Roche says data in hepatitis treatment encouraging

Related Topics

Stocks

   

ZURICH | Thu Apr 19, 2012 11:06am IST

ZURICH (Reuters) - Swiss drugmaker Roche said on Thursday initial data on a protease inhibitor, danoprevir, is encouraging against Hepatitis C.

"The high sustained viral response rates and encouraging safety data show danoprevir is potent and well-tolerated," Roche development head Hal Barron said in a statement.

"Roche's HCV portfolio includes multiple investigational drugs with different modes of action, allowing us to develop tailored treatments that aim to address the future needs of patients with chronic hepatitis C," Barron said.

(Reporting By Katharina Bart)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.